Wegovy denials in California external review
In the California DMHC record, independent physician reviewers decided 675 published external-review cases involving Wegovyand overturned the plan’s denial in 88.7%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
By condition
| Condition | Decisions | Overturned |
|---|---|---|
| Obesity | 633 | 89.4% |
| Pre-diabetes | 23 | 100% |
| Hyperlipidemia | 22 | 95.5% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 672 | 88.8% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 3 | 66.7% |
What the reviewers wrote
Where the denial was overturned
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Wegovy. Obesity is a multi-causal chronic disease. It is the result of long-term positive energy balance along with the development of excess adiposity that, over time, leads to structural abnormalities, physiological derangements, and functional impairments. The disease of obesity increases the risk of developing other chronic diseases and is associated with premature mortality. As with other chronic diseases, obesity is distinguished by multiple phenotypes, clinical presentations, and treatment responses.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Wegovy auto-injector pen. Obesity is a multi-causal chronic disease resulting from long-term energy balance with the development of excess adiposity that leads to structural abnormalities, physiological derangements, and functional impairments. Obesity increases the risk of developing other chronic diseases and is associated with further morbidities. The U.S. Food and Drug Administration (FDA) has approved Wegovy for weight loss in adult patients diagnosed with obesity and a body mass index (BMI) greater than 30 kg/m2.
Where the denial was upheld
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Wegovy. Obesity is a disease associated with a significant increase in mortality and many health risks, including type 2 diabetes mellitus, hypertension, dyslipidemia, and coronary heart disease. Weight loss in patients with obesity is associated with a reduction in mortality. The American Association of Clinical Endocrinologists (AACE) guidelines for the medical care of patients with obesity report that patients with obesity should be considered for treatment with weight-loss medication combined with lifestyle therapy when necessary.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Wegovy. Obesity is a disease associated with a significant increase in mortality and many health risks, including type 2 diabetes mellitus, hypertension, dyslipidemia, and coronary heart disease. Weight loss in patients with obesity is associated with a reduction in mortality. The American Association of Clinical Endocrinologists (AACE) guidelines for the medical care of patients with obesity report that patients with obesity should be considered for treatment with weight-loss medication combined with lifestyle therapy when necessary.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
Why plans deny Wegovy — and what reviewed cases show
Wegovy (semaglutide) is FDA-approved for: chronic weight management; reducing the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established cardiovascular disease and overweight or obesity. An on-label indication can be important evidence when a denial frames the requested use as unproven or cosmetic.
Plan-level weight-loss drug exclusion
Many employer plans exclude the entire “weight-loss drug” benefit category. The denial letter says “not a covered benefit” rather than anything about you. That framing is beatable when the prescription targets a diagnosed condition — obesity is a chronic disease, and Wegovy also carries a cardiovascular indication that has nothing to do with cosmetic weight loss.
BMI documentation gaps
Plans that do cover Wegovy typically require chart-documented BMI plus, at lower BMI levels, a weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, and similar). Denials often turn on the chart not showing the numbers — not on the numbers being wrong.
Step therapy
Plans commonly demand documented failure of a structured lifestyle program or an older, cheaper weight-loss medication first. Reviewers routinely accept a physician's account of prior attempts and reasons alternatives are inappropriate.
Quantity limits and dose-titration denials
Wegovy is titrated stepwise to a maintenance dose. Refill and dose-change requests sometimes get denied as exceeding quantity limits mid-titration — a plumbing problem dressed up as a coverage decision.
If the plan demands you try something else first, request a step-therapy exception: your prescriber attests to prior failures, contraindications, or clinical reasons the preferred alternative is inappropriate. Most states and plan types have a formal exception process with short decision deadlines.
Evidence cited in overturned Wegovy decisions
- Frame obesity as the chronic disease the diagnosis codes say it is — the appeal is about treating a diagnosed condition, not “lifestyle.”
- If cardiovascular disease is in the picture, put the cardiovascular-risk indication front and center: a plan cannot call an FDA-approved cardiac-risk-reduction use cosmetic.
- Document every prior weight-management attempt — programs, medications, outcomes — to preempt the step-therapy rationale.
- Ask the plan for the exact exclusion or criteria language cited; denials that cannot quote plan language tend not to survive review.
The published California record contains 675 external-review decisions involving Wegovy; 88.7% were overturned. This historical rate does not predict another case. For the full class-wide picture — cross-indication strategy, exclusion language, and the record for every GLP-1 drug — see the GLP-1 denial appeal guide.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Wegovy, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY